143 related articles for article (PubMed ID: 21755401)
1. Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial.
Silverman SL; Nasser K; Nattrass S; Drinkwater B
Osteoporos Int; 2012 Mar; 23(3):1069-74. PubMed ID: 21755401
[TBL] [Abstract][Full Text] [Related]
2. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
Lai PS; Chua SS; Chew YY; Chan SP
J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
[TBL] [Abstract][Full Text] [Related]
3. Improving adherence to and persistence with oral therapy of osteoporosis.
Bianchi ML; Duca P; Vai S; Guglielmi G; Viti R; Battista C; Scillitani A; Muscarella S; Luisetto G; Camozzi V; Nuti R; Caffarelli C; Gonnelli S; Albanese C; De Tullio V; Isaia G; D'Amelio P; Broggi F; Croci M
Osteoporos Int; 2015 May; 26(5):1629-38. PubMed ID: 25619634
[TBL] [Abstract][Full Text] [Related]
4. A dedicated Fracture Liaison Service telephone program and use of bone turnover markers for evaluating 1-year persistence with oral bisphosphonates.
van den Berg P; van Haard PMM; van der Veer E; Geusens PP; van den Bergh JP; Schweitzer DH
Osteoporos Int; 2018 Apr; 29(4):813-824. PubMed ID: 29260291
[TBL] [Abstract][Full Text] [Related]
5. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
[TBL] [Abstract][Full Text] [Related]
6. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
[TBL] [Abstract][Full Text] [Related]
7. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T
Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365
[TBL] [Abstract][Full Text] [Related]
8. Influence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: An observational study in Turkish patients with postmenopausal osteoporosis.
Akarırmak Ü; Koçyiğit H; Eskiyurt N; Esmaeilzadeh S; Kuru Ö; Yalçinkaya EY; Peker Ö; Ekim AA; Özgirgin N; Çalış M; Rezvani A; Çevikol A; Eyigör S; Şendur ÖF; İrdesel J;
Acta Orthop Traumatol Turc; 2016 Aug; 50(4):415-23. PubMed ID: 27524671
[TBL] [Abstract][Full Text] [Related]
9. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Freemantle N; Satram-Hoang S; Tang ET; Kaur P; Macarios D; Siddhanti S; Borenstein J; Kendler DL;
Osteoporos Int; 2012 Jan; 23(1):317-26. PubMed ID: 21927922
[TBL] [Abstract][Full Text] [Related]
10. Impact of pharmaceutical care on knowledge, quality of life and satisfaction of postmenopausal women with osteoporosis.
Lai PS; Chua SS; Chan SP
Int J Clin Pharm; 2013 Aug; 35(4):629-37. PubMed ID: 23677816
[TBL] [Abstract][Full Text] [Related]
11. Adherence to osteoporosis medications amongst Singaporean patients.
Cheen MH; Kong MC; Zhang RF; Tee FM; Chandran M
Osteoporos Int; 2012 Mar; 23(3):1053-60. PubMed ID: 21503813
[TBL] [Abstract][Full Text] [Related]
12. Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management.
Ganda K; Schaffer A; Pearson S; Seibel MJ
Osteoporos Int; 2014 Apr; 25(4):1345-55. PubMed ID: 24445732
[TBL] [Abstract][Full Text] [Related]
13. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.
Cosman F; Gilchrist N; McClung M; Foldes J; de Villiers T; Santora A; Leung A; Samanta S; Heyden N; McGinnis JP; Rosenberg E; Denker AE
Osteoporos Int; 2016 Jan; 27(1):377-86. PubMed ID: 26556736
[TBL] [Abstract][Full Text] [Related]
14. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis.
Zhu HM; Qin L; Garnero P; Genant HK; Zhang G; Dai K; Yao X; Gu G; Hao Y; Li Z; Zhao Y; Li W; Yang J; Zhao X; Shi D; Fuerst T; Lu Y; Li H; Zhang X; Li C; Zhao J; Wu Q; Zhao SJ
Osteoporos Int; 2012 Apr; 23(4):1317-27. PubMed ID: 21505910
[TBL] [Abstract][Full Text] [Related]
15. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
Rossini M; Viapiana O; Gatti D; Adami S
Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
[TBL] [Abstract][Full Text] [Related]
16. The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study.
Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver JP; van den Bergh JP; Keown P; Sajjan S
Osteoporos Int; 2018 Feb; 29(2):329-337. PubMed ID: 29110061
[TBL] [Abstract][Full Text] [Related]
17. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
18. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis.
Karlsson L; Lundkvist J; Psachoulia E; Intorcia M; Ström O
Osteoporos Int; 2015 Oct; 26(10):2401-11. PubMed ID: 26282229
[TBL] [Abstract][Full Text] [Related]
19. Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis.
Black DM; Bilezikian JP; Greenspan SL; Wüster C; Muñoz-Torres M; Bone HG; Rosen CJ; Andersen HS; Hanley DA
Osteoporos Int; 2013 Apr; 24(4):1503-11. PubMed ID: 22930240
[TBL] [Abstract][Full Text] [Related]
20. "Twice-a-month" clodronate 200 mg IM: a new dosing regimen and improved therapy adherence in the treatment of postmenopausal osteoporosis.
Muratore M; Quarta L; Calcagnile F; Quarta E
Adv Ther; 2010 May; 27(5):314-20. PubMed ID: 20526703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
